.jpg "Strongbridge Biopharma Plc (NASDAQ: SBBP)")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Strongbridge Biopharma Plc (NASDAQ: SBBP), BioDelivery (NASDAQ: BDSI) and BioLife Solutions (NASDAQ: BLFS) with bullish sentiments.
Strongbridge Biopharma Plc (NASDAQ: SBBP)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Strongbridge Biopharma Plc (NASDAQ: SBBP) today and set a price target of $18. The company’s shares closed yesterday at $7.80.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.5% and a 48.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ACADIA Pharmaceuticals Inc, and Cyclacel Pharmaceuticals.
Currently, the analyst consensus on Strongbridge Biopharma Plc is Strong Buy and the average price target is $14.67, representing an 88.1% upside.
In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $14 price target.
See today’s analyst top recommended stocks >>
BioDelivery (NASDAQ: BDSI)
In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on BioDelivery (NASDAQ: BDSI), with a price target of $4. The company’s shares closed yesterday at $1.75, close to its 52-week low of $1.74.
According to TipRanks.com, Livnat has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.5% and a 25.0% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.
Currently, the analyst consensus on BioDelivery is Moderate Buy and the average price target is $4.25, representing a 142.9% upside.
In a report issued on May 7, Cantor Fitzgerald also maintained a Buy rating on the stock with a $4.50 price target.
BioLife Solutions (NASDAQ: BLFS)
In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on BioLife Solutions (NASDAQ: BLFS), with a price target of $12. The company’s shares closed yesterday at $8.25, close to its 52-week high of $8.45.
McCarthy noted:
“BioLife reported 1Q18 biopreservation media revenue of $3.8, up 22% sequentially and 61% y/y. Margin also continue to rise with increasing volume, coming in at 64% in 1Q. The company is cash flow positive and currently has $9.6M in cash on the balance sheet (including $2.6M from warrants exercised recently). Biolife’s valuation continues to rise as media revenue grows and the company becomes more deeply integrated into an evolving cell therapy space. We are increasing our outyear estimates for cell media revenue which increases our 12-month price target to $12, from $9..”
According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.9% and a 36.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
BioLife Solutions has an analyst consensus of Moderate Buy, with a price target consensus of $9.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
